Physician profile
Benjamin Wiese
NPI 1619402401
$722.43
in general payments reported to CMS, 2019-2025
19 companies · $317 in 2025
The $317 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $165 · 2024: $240 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $722.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $115.04 | 2023-2025 | Prolastin-C Liquid |
| Amgen INC. | $89.73 | 2023-2025 | Tezspire |
| Genzyme Corporation | $85.67 | 2023-2025 | |
| Baxter Healthcare | $50.49 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Resmed Corp | $48.15 | 2025 | |
| Abiomed | $38.29 | 2025 | |
| Verona Pharma, INC. | $36.51 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $33.84 | 2024 | Glassia |
| Regeneron Healthcare Solutions, INC. | $31.65 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.33 | 2024-2025 | Ofev |
| Avadel Cns Pharmaceuticals, LLC | $27.88 | 2023-2025 | Lumryz |
| Boston Scientific Corporation | $25.92 | 2025 | Varithena Administration Pack |
| Insmed, INC. | $18.86 | 2024 | Arikayce |
| Hospira, INC. | $17.57 | 2024 | |
| United Therapeutics Corporation | $15.21 | 2023 | Tyvaso |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.98 | 2025 | Zepbound |
| Pfizer INC. | $14.97 | 2024 | |
| Glaxosmithkline, LLC. | $14.78 | 2024 | Nucala |
| Viatris Specialty LLC | $13.56 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Wiese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.